ID Design Press, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. 2019 Sep 30; 7(18):3026-3029. https://doi.org/10.3889/oamjms.2019.625 eISSN: 1857-9655

Global Dermatology



# Multiple Cutaneous Leiomyomas with Uterus Myomatosus (MCUL) – Two Case Reports and One New Mutation of FH Gene

André Koch<sup>1</sup>, Jacqueline Schönlebe<sup>2</sup>, Aleksandra Vojvodic<sup>3</sup>, Torello Lotti<sup>4</sup>, Uwe Wollina<sup>1\*</sup>

<sup>1</sup>Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital, Dresden, Germany; <sup>2</sup>Städtisches Klinikum Dresden, Institute of Pathology "Georg Schmorl", Dresden, Germany; <sup>3</sup>Military Medical Academy of Belgrade, Belgrade, Serbia; <sup>4</sup>Department of Dermatology, University of Rome "G. Marconi", Rome, Italy

#### **Abstract**

Citation: Koch A, Schönlebe J, Vojvodic A, Lotti T, Wollina U. Multiple Cutaneous Leiomyomas with Uterus Myomatosus (MCUL) – Two Case Reports and One New Mutation of FH Gene. Open Access Maced J Med Sci. 2019 Sep 30; 7(18):3026-3029. https://doi.org/10.3889/oamjms.2019.625

**Keywords:** Fumarate dehydrogenase; Reed syndrome;

\*Correspondence: Uwe Wollina. Department of Dermatology and Allergology, Städtüsches Klinikum Dresden, Academic Teaching Hospital, Dresden, Germany. E-mail: uwollina@gmail.com

Received: 12-May-2019; Revised: 16-Jul-2019; Accepted: 17-Jul-2019; Online first: 30-Jul-2019

Copyright: © 2019 André Koch, Jacqueline Schönlebe, Aleksandra Vojvodic, Torello Lotti, Uwe Wollina. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)

Funding: This research did not receive any financial

Competing Interests: The authors have declared that no

**BACKGROUND:** Reed syndrome or multiple cutaneous leiomyomas with uterine leiomyomas are part of the spectrum of heterozygous hereditary disorders with cutaneous, genital and renal manifestations.

CASE REPORTS: We report two female cases of multiple cutaneous leiomyomas with uterine leiomyomas (MCUL) without renal disease, in particular without cysts or papillary renal carcinoma, aged 52 and 55 years, respectively. The diagnosis of pilar leiomyomas was confirmed by histology and immunostaining for smooth muscle actin and desmin. Both females had a hysterectomy in the past because of uterus myomatosus. In one patient, a new mutation of the FH gene was detected, i.e. a heterozygote c1300\_1301del (p.Cys434Argfs17) mutation in the exon 9 of the FH gene.

**CONCLUSION:** Since MCUL shares features with the genetic cancer syndrome hereditary leiomyomatosis and renal cell carcinoma (HLRCC), these patients need a regular follow-up to prevent the late diagnosis of renal cancer.

### Introduction

The fumarate dehydrogenase (*FH*) gene is located on chromosome 1. In normal cells, FH is localised in both mitochondria and cytosol and catalyses fumarate to malate [1].

Fumarate is a covalent oncometabolite whose accumulation is characteristic for the genetic cancer syndrome hereditary leiomyomatosis and renal cell carcinoma (HLRCC). HLRCC is characterized by germline mutation of the fumarate hydratase (*FH*) gene, which leads to a shift to aerobic glycolysis in the affected cells (Warburg effect) [2]. The disease is autosomal dominant inherited. In homozygotes, FH deficiency is lethal in early childhood [3].

In the medical literature, only about 300 cases

of HLRCC are described with > 150 different mutations [4]. We report on two female patients with the milder type of the disease known as Reed syndrome or multiple cutaneous leiomyomas with uterine leiomyomas (MCUL; MIM 150800) and one new mutation.

## **Case Reports**

#### Case One

A 52-year-old Caucasian woman presented with multiple flat painful tumours concentrated on her left shoulder (Figure 1).

Her medical history was positive for a uterus

3026 https://www.id-press.eu/mjms/index

myomatosus that was surgically removed by hysterectomy. She was otherwise healthy.



Figure 1: Multiple pilar leiomyomas on the left shoulder (case #1)

In her family, her mother had renal cancer at the age of 58 years, her son has multiple cutaneous leiomyomas (Fig. 2).

On examination, we observed multiple flat, livid nodules that were painful on pressure. Their size varied between 1 and 2 cm. The lesions were concentrated above her left should blade, but single lesions were spread all over the body except palmoplantar skin and head and neck.




Figure 2: Family tree of the Case #1

We performed an excision of the most painful lesions. Histopathology disclosed dermal spindle cell tumours without cellular atypias or mitotic activity.

The lesions were well demarcated. Tumour cells were positive for smooth muscle actin and desmin (Figure 3) but Ki67 negative. The diagnosis of pilar leiomyomas was confirmed.

We performed molecular biology analysis of the fumarate hydrogenase (*FH*) gene. Extracted DNA was enriched by Nextera Rapid Capture on Ilumina NextSequ 500 followed by Sanger sequencing, multiplex ligation-dependent probe analysis (MPLA) to detect possible duplications or deletions of exons, and biometric analysis by MutationSurveyor version 3.10,

GeneMarker V2 4.0 and Alamut Visual version 2.6.1 (MVZ Mitteldeutscher Praxisverbund Humangenetik GmbH. Dresden).




Figure 3: Desmin immunostaining of pilar leiomyoma (case #1, x 2)

A heterozygote c1300\_1301del (p.Cys434Argfs17) mutation in the exon 9 of the FH gene could be detected, leading to a loss of function for the reading frame. This mutation has not been described before.

Routine laboratory investigations remained unremarkable. Tumour markers ICA 125 and ICEA were detected by chemiluminescence assays (Roche Diagnostics) and were within the normal range.

She was screened by diagnostic ultrasound, abdominal magnetic resonance imaging, and X-ray of the chest. There was no hint for renal cancer or any other renal disorder.

The diagnosis of MCUL (MIM 150800) was confirmed.

#### Case Two

A 55-year-old Caucasian woman presented with segmental painful tiny brownish nodules and plaques of the left supra- and infraclavicular region (Figure 4). She had a hysterectomy due to a uterus five years ago but no other disorders. Her family history was unremarkable.

A skin biopsy was taken, which disclosed circumscribed dermal tumours composed of interlacing and whorled bundles of smooth muscle cells expressing actin. The tumours appeared yelloworange in van Giessen stain. The diagnosis of pilar leiomyomas was confirmed.

Screening for renal cancer by diagnostic ultrasound and contrast-enhanced computerised tomography (CT) was negative. No molecular analysis was available. Nevertheless, the diagnosis of MCUL (MIN 150800) was confirmed. This case had been reported earlier elsewhere [5]. Until now, no renal

cancer was detected in this patient.






Figure 4: Pilar leiomyomas around the left clavicula (case # 2): a) Overview, b) detail (From Wollina U, Schönlebe J. Reed's syndrome: segmental piloleimyomas type 1 and uterus myomatosus. J Dermatol Case Rep. 2014; 8(3):67-69) [5]

#### **Discussion**

We reported two cases of MCUL, a rare heterozygote FH deficiency, without renal cancer. In the case of heterozygote FH deficiency, fumarate suppresses the homologous recombination DNA repair pathway which is necessary for the repair of DNA double-strand breaks and genomic integrity by succination of proteins. the increases intracellular ferritin concentrations which drives tumour cell proliferation [6].

Hallmark of the disease is hereditary leiomyomatosis seen in > 75% of the affected patients. However, only 46% of affected individuals show cutaneous leiomyomas, benign smooth muscle tumours of the skin of the tumour. These tumours are sensitive to touch and cold and can be painful [7], [8]. Cutaneous pilar leiomyomas are benign tumours with an incidence of 0.04% in pathology files. Other cutaneous leiomyomas are angioleimyoma and dartoic myoma, but the pilar type if the predominant one responsible for 88.5% of all cases [9]. A rare subtype of pilar leiomyoma is represented by symplastic pilar leiomyoma with focal cellular pleomorphism [10]. This particular subtype has been developing reported to be potentially leiomyosarcoma in rare cases [11].

Women with HLRCC are prone to develop multiple leiomyomas of the uterus as well, which leads to uterus myomatosus. Hysterectomy is performed in about 50% in patients younger than 35 years. The disease can cause dysmenorrhea, menorraghias, and menstrual irregularities [12], [13].

Both of our patients had a hysterectomy due to uterine leiomyomas. Both presented with multiple cutaneous pilar leiomyomas. The lesions were segmental in case # 2 and segmental concentrated with single lesions on other body parts in case # 1. Painful lesions were removed by surgery.

The most dangerous feature of HLRCC, however, is the early onset of papillary kidney cancer in the affected families. This tumour has two subtypes. Type 1 is an indolent growing tumour associated with germline mutations of *MET*. It is found in hereditary papillary kidney cancer. Type 2, in contrast, is an aggressive tumour with early metastatic spread. This type is associated with HLRCC. It occurs in about 25% of patients with an average onset at 46 years. It may be without specific symptoms but can cause lumbar back pain or hematuria. Renal cysts are also more common in HRLCC than in the general population [14].

In case # 1, the mother of our index patient had an unspecified renal cancer but no leimyomatosis. This could be an incidental coincidence. In case 2, there was no family history of other members affected by either MCUL or HLRCC. Nevertheless, these patients need a regular live-long follow-up for early detection of renal cell cancer.

In conclusion, MCUL may be considered a forme fruste of HLRCC or a more benign subtype. More investigations are needed.

## **Acknowledgements**

We are grateful for the support of the staff of the MVZ Mitteldeutscher Praxisverbund Humangenetik GmbH, Dresden, in molecular diagnostics.

#### References

- 1. Jardim-Messeder D, Cabreira-Cagliari C, Rauber R, Turchetto-Zolet AC, Margis R, Margis-Pinheiro M. Fumarate reductase superfamily: A diverse group of enzymes whose evolution heterozygotes to the establishment of different metabolic pathways. Mitochondrion. 2017; 34:56-66. https://doi.org/10.1016/j.mito.2017.01.002 PMid:28088649
- 2. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene. 2006; 25(34):4675-4682.

https://doi.org/10.1038/sj.onc.1209594 PMid:16892081

3. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev

3028

Cancer. 2003; 3(3):193-202. <a href="https://doi.org/10.1038/nrc1013">https://doi.org/10.1038/nrc1013</a> PMid:12612654

- 4. Bayley JP, Launonen V, Tomlinson IP. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med Genet. 2008; 9:20. <a href="https://doi.org/10.1186/1471-2350-9-20">https://doi.org/10.1186/1471-2350-9-20</a> PMid:18366737 PMCid:PMC2322961
- 5. Wollina U, Schönlebe J. Reed's syndrome: segmental piloleimyomas type 1 and uterus myomatosus. J Dermatol Case Rep. 2014; 8(3):67-69. https://doi.org/10.3315/jdcr.2014.1178 PMid:25324907 PMCid:PMC4195502
- 6. Kerins MJ, Milligan J, Wohlschlegel JA, Ooi A. Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction. Cancer Sci. 2018; 109(9):2757-2766. <a href="https://doi.org/10.1111/cas.13701">https://doi.org/10.1111/cas.13701</a> PMid:29917289 PMCid:PMC6125459
- 7. Bhola PT, Gilpin C, Smith A, Graham GE. A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC). Fam Cancer. 2018; 17(4):615-620. <a href="https://doi.org/10.1007/s10689-018-0076-4">https://doi.org/10.1007/s10689-018-0076-4</a> PMid:29423582
- 8. Naversen DN, Trask DM, Watson FH, Burket JM. Painful tumors of the skin: "LEND AN EGG". J Am Acad Dermatol. 1993; 28(2 Pt 2):298-300. https://doi.org/10.1016/0190-9622(93)70039-V
- 9. Orellana-Díaz O, Hernández-Pérez E. Leiomyoma cutis and leiomyosarcoma: a 10-year study and a short review. J Dermatol Surg Oncol. 1983; 9(4):283-7. https://doi.org/10.1111/j.1524-4725.1983.tb00803.x PMid:6833615
- 10. Usmani N, Merchant W, Yung A. A case of cutaneous

- symplastic leiomyoma a rare variant of cutaneous pilar leiomyoma. J Cutan Pathol. 2008; 35(3):329-31. https://doi.org/10.1111/j.1600-0560.2007.00803.x PMid:18251750
- 11. Fons ME, Bachhuber T, Plaza JA. Cutaneous leiomyosarcoma originating in a symplastic pilar leiomyoma: a rare occurrence and potential diagnostic pitfall. J Cutan Pathol. 2011; 38(1):49-53. <a href="https://doi.org/10.1111/j.1600-0560.2009.01420.x">https://doi.org/10.1111/j.1600-0560.2009.01420.x</a> PMid:19780873
- 12. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomäki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA; Multiple Leiomyoma Consortium. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002; 30(4):406-410. https://doi.org/10.1038/ng849 PMid:11865300
- 13. Gunnala V, Pereira N, Irani M, Lilienthal D, Pirog EC, Soslow R, Caputo TA, Elias R, Kligman I, Rosenwaks Z. Novel fumarate hydratase mutation in siblings with early onset uterine leiomyomas and hereditary leiomyomatosis and renal cell cancer syndrome. Int J Gynecol Pathol. 2018; 37(3):256-261. https://doi.org/10.1097/PGP.0000000000000423 PMid:28700432 PMCid:PMC5908258
- 14. Menko FH, Maher ER, Schmidt LS, Middelton LA, Aittomäki K, Tomlinson I, Richard S, Linehan WM. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer. 2014; 13(4):637-644. https://doi.org/10.1007/s10689-014-9735-2 PMid:25012257 PMCid:PMC4574691